BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Antibody Drug Conjugates

Sofinnova-Backed Myricx Bio to Join Novartis in Up to $1.5 Billion ADC Deal

Sofinnova Partners co-led the seed investment in 2019 and has supported the company from founding through to exit The proposed acquisition combines th...

July 07, 2026 | News

Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck

THE GATE The choke point nobody puts on the slide Somewhere in the region this quarter, a cell-and-gene developer has everything the pitch deck promised....

July 03, 2026 | Analysis

Nona Biosciences and Lonza Partner to Develop Next-Generation BBB-Crossing Platform for CNS Therapies

Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery and development through innovative technology platforms, announced ...

July 03, 2026 | News

Lonza Expands Commercial ADC Payload-Linker Manufacturing at Visp to Support Growing Oncology Pipeline

Lonza to expand payload-linker manufacturing capacity in Visp (CH) to support the rapidly growing antibody-drug conjugate (ADC) market Investment...

July 01, 2026 | News

Ever Supreme Advances Off-the-Shelf CAR-T Therapy CAR001 to Phase IIa After Positive Phase I Safety Review

Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announced on June 28 that CAR001, its proprietarily developed, allogeneic, "off-the-shelf" CAR...

July 01, 2026 | News

Billions on Bioconjugation: Is APAC Building the Right ADC Capacity — or Too Much?

In Songdo, on the reclaimed waterfront west of Seoul, a 202,000-square-metre construction site is becoming the most expensive single statement Kore...

June 19, 2026 | Analysis

Akeso Enrols First Patient in Phase Ib/II Trial of Next-Generation HER3 ADC AK138D1 for Advanced Breast Cancer

Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally...

June 17, 2026 | News

Can the 'Pharmacy of the World' Survive Its Own Scandals?

In late September and early October 2025, children in the central Indian state of Madhya Pradesh began arriving at hospitals with the same grim trajectory:...

June 08, 2026 | Analysis

Mabwell's First In Class Autoimmune Antibody 9MW5211 Wins China Clinical Trial Approval for IBD

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its independently...

June 08, 2026 | News

Innovent's Arcotatug Tavatecan Meets Phase 3 Endpoint in Advanced Gastric Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

June 05, 2026 | News

Samsung Epis Holdings Establishes First Global R&D Hub in Beijing to Advance ADC and Novel Drug Development

Establishes its first global research base as part of strategic new business expansion under the holding company structure Ÿ B...

June 03, 2026 | News

Pfizer And Innovent Biologics Forge Global Oncology Alliance Covering 12 Cancer Programs

Pfizer Inc. and Innovent Biologics, Inc. announced the companies have entered into a strategic global licensing and collaboration agreement for the r...

June 01, 2026 | News

Ingenia Therapeutics Secures KRX Approval For IPO Amid Advancing TIE2 Targeted Pipeline

Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that the company has receive...

May 26, 2026 | News

LOTTE Biologics Expands Strategic Partnership With Ottimo Pharma To Advance OTP 01 Commercial Readiness

LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developi...

May 19, 2026 | News

Stay Connected